12 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
. Name and address of MA holder: Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
for pulmonary arterial hypertension.
Kaival Brands Innovations Group, Inc
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
internal and external innovation to best serve patients."
As part of the agreement, Ascentage Pharma
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
.This innovative research collaboration has generated one of the largest cohort data sets globally of HAE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness
nvure8gzobqgnk9h2m4x26m3xz4nd3n0b eplcqq2bfow3drl
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
w48dyq3timef ieyc
SCLX
TAK
14 May 24
"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
co6dzi6
ACIU
TAK
13 May 24
in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer's disease
n975yjyogf0ee3z61agmvu24jq7o7us5au7vyzg
ACIU
TAK
13 May 24
.
"As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change
rkyjrz5oltc29e0m1mdtelom9xfxyb016k
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
dvknnfeglaat91kp2hmkd645jg6xoa2r7sl
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
h2j7fcmevbc7gepc1l8z2aql81vewwu iv5lxhdlfa310
TAK
27 Mar 24
gastrointestinal diseases is unwavering. Alongside our continuous work on innovative treatments within our gastroenterology portfolio, we recognize the significant
- Prev
- 1
- Next